Development and commercialisation
Biota and Daiichi Sankyo co-own a range of second generation influenza anti-virals, of which Inavir is the lead product.
Note the use of the phrase "is the lead product". There must be more to come. Toot Toot !
- Forums
- ASX - By Stock
- BTA
- relenza sales on the rise
relenza sales on the rise, page-3
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BTA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, CEO
Anthony Noble
CEO
SPONSORED BY The Market Online